Align Technology Q3 revenue slightly beats estimates
Overview
US clear aligner maker's Q3 revenue grew yr/yr, a slight beat of analyst expectations
Adjusted EPS for Q3 beat analyst expectations
Company repurchased about 627,000 shares in Q3, plans up to $300 mln buyback in Q4
Outlook
Align sees Q426 worldwide revenue between $1.0 bln and $1.02 bln
Company expects 2026 Clear Aligner volume and revenue growth up 5% to 6% year-over-year
Result Drivers
CLEAR ALIGNER VOLUME - Co said growth was driven by record doctor submitters, higher shipments, improved utilization, and broad-based international growth
EXPENSE MANAGEMENT - Co attributed improved operating margin to disciplined expense management and productivity improvements
SCANNER PLACEMENTS - Co said double-digit growth in iTero scanner placements contributed to performance
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Slight Beat* | $1.01 bln | $1.005 bln (12 Analysts) |
Q3 Adjusted EPS | Beat | $2.80 | $2.78 (14 Analysts) |
Q3 EPS | $1.90 | ||
Q3 Adjusted Net Income | Slight Beat* | $198.90 mln | $198.21 mln (11 Analysts) |
Q3 Net Income | $135 mln | ||
Q3 Adjusted Operating Margin | 24.40% | ||
Q3 Gross Profit | $697.47 mln |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 9 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Align Technology, Inc. is $197.39, about 29.9% above its October 27 closing price of $151.95
The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 14 three months ago
Reuters Recommended Reads
Oct 28 - Boston Scientific warns of tough 2027 on China pricing, heart-device weakness
Oct 28 - Straumann sees North America stabilising, China demand improving after Q3 beat
Oct 28 - Boston Scientific Q3 revenue beats estimates despite cybersecurity disruption
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)